Kornimate/medical-research-clean huggingface dataset:
research-action in hematology from hospitalization to home

Conditions: Hematologic Cancer

Summary: objective : to study and support the hospitalization and the return home of patients with the help of a psychological follow-up started in a hospital institution and which will continue in the patient's home, based on the concepts of transitionality and narrativity. material and method to do this, the subjects will benefit from psychological interviews where they will freely discuss what concerns them, whether it is illness, treatment, returning home, or any other personal subject. they will be divided into two groups of 5 patients each, one of the groups will benefit from follow-up in an institution as contracted for several years between the institute of hematology and the psychologists of the umdsp, another from the same follow-up but with the presence of the psychologist at the time of discharge extended to the patient's home after leaving the hospital for a period of 2 months. to ensure a certain consistency in the evaluation criteria, these will be standardized in the form of questionnaires completed blindly by the patient, a caregiver and the investigator, at 3 key times of the research (entry, discharge from hospital, two months after this discharge) device tested: the aim of this work is to test the benefits of a device based on transitionality, which can limit, thanks to the restoration of the symbolization process, the deleterious effects of each of the stages imposed by the disease, the care and the resumption of autonomy once the active phase of care has passed. narrativity is also at the heart of this transitional device. it makes it possible to evoke the present experience of the patient in connection with future projects and in the continuity of past, potentially traumatic events. it opens onto a dynamic temporal perspective where the trauma freezes. the whole process promotes the subjective reappropriation of the experience and a psychic well-being.


Eligibility criteria:
inclusion criteria: * patient hospitalized protected hematology unit * patient with haematologic cancer * patient requesting psychological assistance or accepting proposed psychological assistance * signed informed consent exclusion criteria: * patient refusing to participate * patient not able to participate
collaborative-care rehabilitation after dysvascular amputation

Conditions: Diabetes Complications; Peripheral Arterial Disease

Summary: the objective of this study is to examine the feasibility of using a collaborative-care, home-based rehabilitation program to improve functional outcomes for people recovering from lower limb amputation caused by vascular problems and/or diabetes complications. the primary hypothesis is that the rehabilitation program will result in greater improvements in performance-based and participant-reported measures of physical function, compared to standard of care after outpatient rehabilitation.


Eligibility criteria:
inclusion criteria: 1. diabetes and/or peripheral artery disease 2. unilateral transtibial amputation \< 6 months prior to screening 3. household ambulation using definitive prosthesis prior to baseline testing 4. participation in physical rehabilitation at time of baseline testing 5. live within 45 minutes of a participating clinic exclusion criteria: 1. require wheelchair for mobility (use prosthesis for transfers only) 2. ankle-level or above amputation on contralateral limb 3. traumatic or cancer-related amputation 4. uncontrolled heart condition 5. acute systemic infection 6. pregnancy 7. decisionally challenged 8. prisoners

Keywords: amputation rehabilitation exercise movement
intrauterine insemination predictor factors

Conditions: Infertility

Summary: multiple studies have reported on the impact of factors such as female age, duration of infertility, type of infertility, hormone levels (i.e. amh, fsh, estradiol, progesterone), use of different ovarian stimulation protocols, timing/induction of ovulation, number of pre-ovulatory follicles, endometrial thickness by the time of ovulation, sperm parameters (i.e. concentration, progressive motility, morphology, total motile sperm count \[tmsc\], inseminating motile count \[imc\]) and sperm washing procedures. also the influence of body mass index and smoking on iui outcome have been studied before. however, results on the predictive value of these parameters remain highly contradictory. the aim of the study is to examine the value of different variables in the prediction of iui success to develop a clinically useful predictive model of pregnancy and live birth.


Eligibility criteria:
inclusion criteria: * couples had been diagnosed with infertility according to who definition (failure to achieve a clinical pregnancy after 12 months or more of regular unprotected sexual intercourse) * at least one permeable tube * a motile sperm concentration post treatment of 1×106/ml on the day of the semen analysis
effect of lidocaine plus dexmedetomidine infusion on ponv

Conditions: Lidocaine; Dexmedetomidine; Nausea and Vomiting, Postoperative

Summary: background: few researches have manifested that intravenous (iv) lidocaine or dexmedetomidine decreased the incidence of postoperative nausea and vomiting (ponv). the investigators investigated whether iv lidocaine plus dexmedetomidine infusion could better reduce the incidence of ponv after laparoscopic hysterectomy. methods: one hundred and twenty women with elective laparoscopic hysterectomy were randomly divided into two groups: patients in the lidocaine combined with dexmedetomidine group (ld group, n=60) received lidocaine (1.5 mg/kg loading, 1.5 mg/kg/h infusion) and dexmedetomidine (0.5 μg/kg loading, 0.4 μg/kg/h infusion) respectively. patients in the control group (con group, n=60) received the equal volume of saline. primary outcome was the incidence of the first 48 h nausea, vomiting and ponv after surgery. the secondary outcomes included perioperative propofol and remifentanil consumption, postoperative fentanyl requirement, ramsay sedation score, and bradycardia during post-anaesthesia care unit (pacu) stay.


Eligibility criteria:
inclusion criteria: * american society of anesthesiologists (asa) physical statusⅰand ⅱ * aged 40-55 years * scheduled for elective laparoscopic hysterectomy exclusion criteria: * history of allergy to local anesthetics * severe respiratory disease * renal or hepatic insufficiency * history of preoperative opioids medication and psychiatric * preoperative bradycardia * preoperative atrioventricular block * subjects who experienced severe hypotension (mean arterial pressure \[map\] \<60 mmhg) or bradycardia (heart rate \[hr\] \<40 bpm), urticaria, or arrhythmia during lidocaine and dexmedetomidine infusion period

Keywords: lidocaine dexmedetomidine postoperative nausea and vomiting laparoscopic hysterectomy
barostim therapy™ in heart failure with reduced ejection fraction

Conditions: Heart Failure

Summary: the purpose of this registry (nct02880618) is to evaluate the effect of barostim therapy with the barostim neo system in the commercial setting in subjects recently implanted under the ce-marked indication for heart failure with reduced ejection fraction (hfref).

summary: the cvrx barostim therapy in heart failure with reduced ejection fraction (hfref) registry will be performed with subjects who have been recently implanted with the barostim neo system in accordance with ce-mark approved criteria for heart failure. subjects must be enrolled within 30 days from implant. up to 500 subjects will be enrolled at up to 50 sites. data should be obtained from standard of care measurements taken prior to implant, at enrollment/baseline, and at 3, 6, and 12 months after the device was implanted, at which time each subject will be exited from the registry. eligibility: subjects can be included in the heart failure with reduced ejection fraction registry if they were implanted in the past 30 days and meet the ce-mark approved indications, and are not contraindicated, for the barostim neo system in the treatment of heart failure. the barostim neo system is indicated for subjects with heart failure, defined as new york heart association (nyha) functional class iii and left ventricular ejection fraction (lvef) ≤ 35% despite being treated with the appropriate heart failure guideline directed therapy. the contraindications are: * bilateral carotid bifurcations located above the level of the mandible * baroreflex failure or autonomic neuropathy * uncontrolled, symptomatic cardiac bradyarrhythmias * carotid atherosclerosis that is determined by ultrasound or angiographic evaluation to be greater than 50% * ulcerative plaques in the carotid artery as determined by ultrasound or angiographic evaluation objectives: to describe change in the following measures at 3, 6 and 12 months compared to pre-implant baseline: * new york heart association (nyha) class * six minute hall walk * echocardiogram measures * biomarkers (e.g. nt-pro bnp, egfr, troponin hst, cystatin c). evaluate health care utilization over follow-up, such as heart failure hospitalizations. describe device programming and utilization

Eligibility criteria:
inclusion criteria: * subject has heart failure, defined as new york heart association (nyha) functional class iii and left ventricular ejection fraction (lvef) ≤ 35% despite being treated with the appropriate heart failure guideline directed therapy * subject has been implanted with the barostim neo system in the past 30 days * subject has signed an ethics committee approved informed consent form exclusion criteria: * bilateral carotid bifurcations located above the level of the mandible * baroreflex failure or autonomic neuropathy * uncontrolled, symptomatic cardiac bradyarrhythmias * carotid atherosclerosis that is determined by ultrasound or angiographic evaluation to be greater than 50% * ulcerative plaques in the carotid artery as determined by ultrasound or angiographic evaluation
heart and hands study ii: a retrospective data collection & analysis project

Conditions: Thrombosis

Summary: a recent pilot study conducted at healtheast found use of manual pressure with the softseal hemostatic pad for 15 minutes was successful in 9 out of 10 people fully anticoagluated using 4 french radial sheath. there was no evidence of radial artery occlusion in this small sample and bleeding was limited to grade 1. this evidence supports a larger retrospective study to confirm these results and define an alternative to the tr band use post radial artery access for cardiac catheterization. primary objective determine the incidence of arterial bleeding after real-world use of softseal hemostatic device at a transradial access site with a 4 french system with with manual pressure by compression of the ulnar artery. secondary objective determine the incidence of thrombosis at the access site in all subjects as presence of thrombus in the radial artery by reverse barbeau test; the incidence of changes in circulation, movement and sensation (cms) in the hand and wrist on the impacted hand; and the incidence of hematoma and ecchymosis, assessed just prior to discharge.

this is a non-randomized, retrospective study to observe the usefulness of softseal. only patients with radial procedures will be used in this study. study procedure for patients with a 4 french catheter, softseal will be applied per physician instruction. current protocol for use includes compression of ulnar artery on the same visit. any bleeding observed at the site after manual pressure hold with softseal will constitute a failure to achieve hemostasis patient will be managed per standard of care (soc). data plan following completion of clinical care we will extract data related to primary and secondary objectives. data extraction will include documentation of cms, reverse barbeau and incidence of hematoma and ecchymosis. any additional statistical analysis or manuscript writing will be done as part of a separate agreement to be met with the approval of both haelatheast medical research institute and chitogen. sample size calculation since this is a real-world data analysis project with no control group, there is not a sample size calculation. we believe approximately 50 patients will be enough to provide an understanding of use instructions for the softseal product.

Eligibility criteria:
inclusion criteria: * transradial access site with a 4 french system -\>18 years old exclusion criteria: * current oral anti-coagulation therapy * prior participation in this study * positive standard-of-care pregnancy test * investigator discretionary exclusions * patient on dialysis * gfr \<30

Keywords: radial artery hemostasis angiography
prospective, randomized study of 2 different wound dressings

Conditions: Hip-surgery; Knee-surgery; Spinal-surgery

Summary: the primary objective of this investigation is to evaluate the performance of a self-adhesive absorbent post-operative dressing coated with a soft silicone layer in minimize the risk of the development of blistering in subjects after hip or knee arthroplasty or spinal surgery in comparison to a standard wound dressing the secondary objectives are to evaluate: * the performance of the dressing * the comfort, conformability and the acceptability of the dressing * pain before, during and after dressing removal * the overall cost regarding dressing wear time, time to do dressing change and personal resources needed

a monocentre, post ce-mark, randomized clinical trial will be conducted at the university of cologne, department of orthopedics and trauma surgery. male or female subjects, 18 years and above, undergoing hip, knee or spinal surgery with an expected hospital stay for 4 days or more will be included in the trial. individual trial duration will be for 7 days (follow-up). two hundred subjects will be included in the trial, i.e. 100 subjects per arm. the treatment arm (either new or standard wound dressing) will be assigned by randomization stratified by type of surgery (i.e. hip, knee or spine). aes/ades/unexpected events with the device may be documented by relevant photos at time. all photos shall include a sticker marked with subject code, visit number/date and time. outcome measures primary variable: • development of blistering from day 0 to day 6 post surgery photo documentation will be evaluated in a blinded manner by the clinical evaluation committee (cec). secondary variables: * other wound complications (i.e. leakage, inflammation, infection) * number of dressing changes * pain before, during and after dressing removal (va scale) * performance and acceptability of the dressing (4 point rating scale)

Eligibility criteria:
inclusion criteria: 1. age ≥18years 2. have an expected total length of stay of 4 or more days 3. undergoing elective primary arthroplasty of the hip or knee or spinal surgery 4. undergoing hip surgery with a standard access 5. give their written informed consent to participate exclusion criteria: 1. dressing size does not fit the incision area 2. known allergy/hypersensitivity to any of the components of the dressing 3. multi-trauma 4. undergoing arthroplasty or spine surgery due to tumour or infection? 5. fractures 6. wound at the surgical site prior to surgery 7. neurological deficit of operated side (hemiplegia, etc.) 8. subject has documented skin disease at time of enrolment, as judged by the investigator

Keywords: wound dressing silicone standard wound dressing
efficacy and safety of delgocitinib cream in adolescents 12-17 years of age with moderate to severe chronic hand eczema

Conditions: Chronic Hand Eczema

Summary: the purpose of this trial is to test if delgocitinib cream is effective at treating chronic hand eczema (che) and what side effects it may have, in children aged 12-17. there will be a range of assessments that rate the severity and extent of che symptoms, general health and quality of life. delgocitinib is a cream that suppresses specific processes in the body's response to diseases like che, such as inflammation. the trial will last up to 22 weeks and has a 1-4 week screening period, a 16 week treatment period and a 2 week follow up period. during the treatment period each child will use either delgocitinib cream or a cream vehicle twice a day. which cream each child receives is chosen randomly by a computer. the cream vehicle is made of the same ingredients as the delgocitinib cream except for the active medical ingredient. there will be 8 visits with the trial doctor.


Eligibility criteria:
inclusion criteria: * diagnosis of che, defined as hand eczema that has persisted for more than 3 months or returned twice or more within the last 12 months. * disease severity graded as moderate to severe at screening and baseline according to iga-che. * subjects who have a documented history of inadequate response to treatment with tcs or for whom tcs are documented to be otherwise medically inadvisable. exclusion criteria: * concurrent skin disease on the hands. * clinically significant infection on the hands. * systemic treatment with immunosuppressive drugs, immunomodulating drugs, retinoids, or corticosteroids within 28 days prior to baseline (steroid eyedrops and inhaled or intranasal steroids corresponding to up to 1 mg prednisolone for allergic conjunctivitis, asthma, or rhinitis are allowed). * use of tanning beds, phototherapy, or bleach baths on the hands within 28 days prior to baseline. * previous or current treatment with jak inhibitors (including delgocitinib/leo 124249), systemic or topical. * cutaneously applied treatment with immunomodulators or tcs on the hands within 14 days prior to baseline. * use of systemic antibiotics or cutaneously applied antibiotics on the hands within 14 days prior to baseline. * other cutaneously applied therapy on the hands (except for the use of subject's own emollients) within 7 days prior to baseline. * cutaneously applied treatments in regions other than the hands, which could interfere with clinical trial evaluations or pose a safety concern within 7 days prior to baseline. * any disorder which is not stable and could: * affect the safety of the subject throughout the trial. * impede the subject's ability to complete the trial.
management of dyslipidemia in adult type 2 diabetes patients in india

Conditions: Dyslipidemia; Type 2 Diabetes Mellitus

Summary: the purpose of study to assess the control of dyslipidemia in the indian diabetic population treated with any hypolipidemic agent.


Eligibility criteria:
inclusion criteria: * adult who is a known type 2 diabetic as per the ada 2010 criteria or controlled diabetic (taking any antidiabetic medication) * patients in the study will have been on lipid lowering drugs at a stable dose for the last three months before the designated study visit. exclusion criteria: * type 1 diabetic patients * patients with a history of hepatic or renal diseases * hypertension due to organic diseases

Keywords: management of dyslipidemia in type 2 diabetes mellitus adult patients in india dyslipidemia control rates in type 2 diabetic mellitus patients
idiopathic diseases of man

Conditions: Rare Disease; Idiopathic Disease

Summary: this research is being done to learn more about possible genetic causes of currently undiagnosed conditions, and to find out how the development of new technologies, such as dna sequencing, can increase knowledge of the role genetic variants play in disorders and possibly how genetic variants may help de-termine the best treatment options. the recent development of new technologies has increased our ability to understand how genetic mutations are associated with disease. using these technologies to find the genetic variants responsible for rare diseases is a rapidly growing field and has already begun to transform the way conditions with unknown causes are diagnosed and treated. hypothesis: identification of new genomic variants associated with idiopathic diseases and/or diseases of unknown etiology will advance medical knowledge about rare and common diseases.


Eligibility criteria:
inclusion criteria: 1. individual with rare disorder with previous unknown etiology. 2. individual with known disorder that does not respond to conventional treatment. 3. individual experienced a rare adverse event that was a result of the administration of a pharmacologic or biologic agent, immunization or device. 4. individual is a family member of the affected individual. - exclusion criteria: 1. unwilling or unable to grant informed consent if they do not have a legal guardian who has authority to sign a consent form on their behalf. 2. have a significant medical, affective, or psychiatric condition that in the investigator's opinion may interfere with subject's study participation.

Keywords: idiopathic diseases family member of the affected individual unknown etiology
thoracoabdominal arortic cta study

Conditions: Thoracic Aortic Aneurysm

Summary: the purpose of this study is to compare the contrast agents and imaging techniques used for thoracoabdominal aortic imaging in ct. imaging parameters and contrast volume are changed and adjusted based on the contrast agent, since contrast agents have varying iodine concentrations. if the contrast iodine concentration is higher, it may be possible to adjust the imaging parameters and lower the overall radiation dose to the patient.


Eligibility criteria:
inclusion criteria: * patients undergoing thoracoabdominal aortic (taa) cta * able to provide informed consent * body mass index (bmi) equal to or less than 30 exclusion criteria: * creatinine greater than 2.0 * allergy to contrast media * pregnant women

Keywords: suspected or confirmed taa computed tomography angiography cta contrast agent radiation dose thoracoabdominal aortic aneurysm
impact of ketoflex 12/3 diet on parkinson's disease symptoms: a clinical study

Conditions: Parkinson&#39;s Disease; Parkinson

Summary: this study aims to investigate the effects of the ketoflex 12/3 diet on motor and non-motor symptoms in patients with parkinson's disease. participants will follow the ketoflex 12/3 dietary regimen, and their cognitive function, motor symptoms, sleep patterns, gastrointestinal health, and overall well-being will be assessed through standardized clinical scales. the study will help determine whether a plant-based ketogenic diet combined with intermittent fasting can have a beneficial impact on parkinson's disease progression.

parkinson's disease is a progressive neurodegenerative disorder characterized by motor and non-motor symptoms. emerging evidence suggests that dietary interventions, particularly ketogenic diets and intermittent fasting, may play a role in neuroprotection and symptom management. this study investigates the effects of the ketoflex 12/3 diet, a plant-based ketogenic dietary approach combined with intermittent fasting, on parkinson's disease progression. clinical assessments will include unified parkinson's disease rating scale (updrs), mini-mental state examination (mmse), depression and anxiety scales, sleep quality assessments, and gastrointestinal health evaluations. the study aims to provide new insights into the potential benefits of metabolic-based nutritional interventions in parkinson's disease patients.

Eligibility criteria:
inclusion criteria: * diagnosed with parkinson's disease * age between 40-85 years * native turkish speakers * able to comply with the study protocol exclusion criteria: * history of alcohol or substance dependence * diagnosis of chronic renal failure * presence of neuromuscular disorders * having amalgam dental fillings and/or failure to remove them according to the smart protocol * severe vitamin deficiencies that have not been corrected prior to the study

Keywords: parkinson's disease ketogenic diet intermittent fasting ketoflex 12/3 neurodegenerative disorders